The present invention discloses the process for the preparation of paliperidone and its pharmaceutically acceptable salts comprising (a) condensing 2-amino-3-hydroxy- pyridine with 2-acetylbutyro lactone in the presence of an acid catalyst to isolate 9- hydroxy-3-(2-hydroxyethyl)-2-rnethyl-4H-pyrido[l 2-a] pyrimidin-4-one; treating 9- hydroxy-3-(2-hydroxyethyl)-2-methyl-4H-pyrido[l 2-a] pyrimidin-4-one with a chlorinating agent; hydrogenating the product in the presence of one or more lewis acid...

The present invention relates to rasagiline (I) and its pharmaceutically acceptable salts. The invention also relates to improved processes for the preparation of rasagiline and its pharmaceutically acceptable salts. The invention also relates to pharmaceutical compositions that include the pharmaceutically acceptable salts of rasagiline and use of the compositions for treating the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa.

A process of manufacturing of Rosuvastatin Potassium of formula (1) is disclosed. The process comprises the steps of (a) treating Rosuvastatin protected compound of formula (II) wherein R and R are same or different having C-C carbon atom or hydrogen or R and R can combine together to afford a cyclic structure comprising a junction atom as carbon or metal atom such as Si (silicon); with an inorganic base of the kind such as herein described having potassium as cation in a suitable solvent to for...

The present invention relates to aqueous nasal spray solutions of fluticasone and olopatadine. In particular the present invention relates to a stable aqueous nasal spray solution comprising combination of fluticasone and olopatadine or pharmaceutically acceptable salts thereof and process of manufacturing thereof. The aqueous composition is particularly suitable for topical administration into the nose in the treatment of inflammatory conditions.

The present invention discloses two new related substances (6) and (7) of Anastrozole synthesis from Q.A. Salt (5) as in Scheme—1 and purification procedures to get Anastrozole (1) free from (6) and (7).

Disclosed are new salts of Clopidogrel viz. Clopidogrel mesylate Clopidogrel besylate and Clopidogrel tosylate methods for their preparation and pharmaceutical compositions containing them and their use in medicine.

The present invention relates to stable pharmaceutical compositions of clopidogrel or salts thereof for parenteral administration. The invention relates to pharmaceutical compositions containing concentrate of clopidogrel or pharmaceutically acceptable salts thereof which can be mixed with suitable aqueous vehicle for preparation of infusion solution suitable for administration to patients. Such compositions exhibit excellent stability. The invention also includes process of preparation of such ...

Disclosed herein are the improved processes for the preparation of different forms of (S)-(+)-Clopidogrel besylate pharmaceutical compositions containing them and their use in medicine.

The invention relates to processes for the preparation of olmesartan medoxomil and intermediates thereof. More particularly it relates to a process for the preparation of ethyl-4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-[2-(triphenylmethyl)-2H-tetrazol- 5yl]- biphenyl-4-yl]methyl]imidazole-5-carboxylate and its use in the preparation of olmesartan medoxomil. The invention also relates to crystalline olmesartan medoximil and pharmaceutical compositions that include the crystalline olmesartan med...